Detalhe da pesquisa
1.
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Gut
; 64(6): 948-56, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25080450
2.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lancet
; 384(9956): 1756-65, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25078309
3.
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
Gastroenterology
; 146(2): 430-41.e6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24184810
4.
Telaprevir for retreatment of HCV infection.
N Engl J Med
; 364(25): 2417-28, 2011 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21696308
5.
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Hepatology
; 58(2): 514-23, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359491
6.
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Hepatology
; 58(2): 524-37, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23348636
7.
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
J Hepatol
; 58(3): 488-94, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23183521
8.
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
J Hepatol
; 58(5): 883-9, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23321318
9.
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Ann Hepatol
; 11(1): 15-31, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22166557
10.
Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.
Hepatology
; 52(4): 1193-200, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20658462
11.
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.
Hepatology
; 50(3): 717-26, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19585653
12.
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Hepatology
; 48(2): 385-97, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18570306
13.
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Hepatology
; 48(4): 1033-43, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18697207
14.
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
Liver Int
; 28(4): 477-85, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18339074
15.
Why do we need another interferon?
Gastroenterology
; 139(4): 1084-6, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20800652
16.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Ann Intern Med
; 140(5): 346-55, 2004 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-14996676
17.
High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
Hepatology
; 48(4): 1349-50, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18821613
18.
Developments in the treatment of chronic hepatitis C.
Expert Opin Investig Drugs
; 11(4): 515-28, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11922860
19.
Simeprevir for the treatment of chronic hepatitis C.
Expert Opin Pharmacother
; 14(18): 2581-9, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24138198
20.
Antifibrotics for chronic hepatitis C.
Clin Liver Dis
; 13(3): 365-73, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19628154